Overview
Sialoadenitis, characterized by inflammation of the salivary glands, encompasses a spectrum of conditions ranging from chronic inflammatory processes to acute inflammatory responses triggered by various etiologies. This condition can significantly impact quality of life, particularly in pediatric populations and adults with specific comorbidities. The pathophysiology often involves initial factors such as hyposalivation and qualitative alterations in saliva, exacerbated by external triggers like radiation and environmental factors. Additionally, immune complex formation, foreign body reactions, and neuropeptide imbalances contribute to the development and progression of sialoadenitis. Understanding these multifaceted mechanisms is crucial for effective diagnosis and management.
Pathophysiology
Sialoadenitis arises from chronic inflammatory processes that can lead to microabscesses within the salivary glands, often initiated by hyposalivation and qualitative changes in saliva composition. These initial conditions can be further aggravated by external factors such as actinic radiation and environmental stressors, which amplify the inflammatory response [PMID:40818136]. In certain contexts, viral agents, notably characterized in rat models, have been implicated in inducing sialoadenitis with clinical and histological features akin to natural outbreaks, underscoring the potential role of infectious agents in human cases [PMID:6289776]. Foreign body reactions, though uncommon, can also precipitate chronic obstructive sialoadenitis, particularly in the submandibular gland, highlighting the importance of thorough physical examinations to identify such triggers [PMID:27438453].
Neurological factors play a significant role, as evidenced by studies in non-obese diabetic (NOD) mice, where reduced levels of neuropeptides such as substance P (SP) and vasoactive intestinal peptide (VIP) correlate with diminished glandular responsiveness and contribute to the pathophysiology of autoimmune-related sialoadenitis [PMID:9010501]. Salivary protein dynamics also exhibit circadian rhythms, with alterations in proton signal intensities indicative of underlying pathology in patients suspected of having sialoadenitis [PMID:1741702]. Furthermore, immune complex formation involving salivary antigens and external antibodies can trigger acute inflammatory responses, as demonstrated by experimental models where antiserum introduction into rat parotid glands induced severe sialoadenitis [PMID:956953].
Epidemiology
Sialoadenitis predominantly affects adult males, with epidemiological data indicating a male-to-female ratio of approximately 2:1 and a mean age of onset around 40.9 years [PMID:40818136]. This demographic skew suggests a higher incidence in middle-aged men, possibly influenced by occupational exposures or lifestyle factors. In pediatric populations, particularly those with neurodisabilities, sialorrhoea (excessive drooling) is a common manifestation, affecting 40% to 60% of affected children and significantly impacting their quality of life [PMID:39888937]. Susceptible rodent models have shown consistent virulence of certain pathogens across multiple passages, indicating their potential role in recurrent outbreaks [PMID:6289776]. These epidemiological patterns underscore the need for tailored preventive and therapeutic strategies across different age groups and underlying conditions.
Clinical Presentation
The clinical presentation of sialoadenitis varies widely, reflecting its diverse etiologies. Chronic sialadenitis, often categorized as Sialadenitis Granulomatosa (SG) and Chronic Granulomatous Sialadenitis (CG), manifests with symptoms ranging from mild lip reddening to severe manifestations such as suppuration, lip swelling, erythema, ulceration, and crust formation, with the lower lip being most frequently affected [PMID:40818136]. In animal models, infection with specific pathogens like CARS results in enlarged submaxillary glands and characteristic plaque formations, mirroring human clinical presentations [PMID:6289776]. Sialorrhoea, characterized by excessive salivation, can occur in children without overt dental issues or systemic diseases, emphasizing its potential as a primary symptom [PMID:42017726].
Advanced cases may present atypical symptoms, such as masseteric hypertrophy alongside bilateral parotid gland involvement, indicating the complexity of clinical presentations beyond typical painless swelling [PMID:14649690]. Treatment responses, including botulinum toxin type A injections, have shown efficacy in managing relative sialorrhoea, highlighting the utility of targeted interventions [PMID:11784340]. Additionally, studies in typically developing children with sialorrhoea suggest that drooling can persist even in the absence of neurological disorders, pointing to developmental delays in saliva control mechanisms [PMID:11737025]. These varied presentations underscore the importance of a comprehensive clinical evaluation to identify underlying causes and tailor appropriate management strategies.
Diagnosis
Diagnosing sialoadenitis requires a multifaceted approach, integrating clinical findings with histopathological evidence. Histopathological confirmation typically involves identifying key criteria such as sialectasia (dilated ducts), chronic inflammation, oncocytic or mucosal metaplasia, and ductal mucin presence, with at least two of these features necessary for diagnosis [PMID:40818136]. Diagnostic tools like the Drooling Impact Scale (DIS) have proven valuable in quantifying the impact of sialorrhoea on daily life, aiding in both clinical assessment and trial outcomes [PMID:39888937]. Multidisciplinary consultations, including dental specialists, are essential to evaluate salivary gland function and rule out secondary causes like dental issues or foreign bodies [PMID:42017726].
Advanced diagnostic modalities, such as proton NMR spectroscopy, reveal significant differences in salivary protein concentrations between affected and healthy individuals, offering objective biomarkers for suspected cases [PMID:1741702]. Experimental models, such as intraductal instillation of antiserum to salivary antigens, replicate acute sialoadenitis, providing insights into both diagnostic criteria and underlying mechanisms [PMID:956953]. Additionally, alterations in neuropeptide levels, particularly reduced SP and VIP concentrations, in submandibular and parotid glands, may serve as early biomarkers for autoimmune-related sialoadenitis in susceptible populations like NOD mice [PMID:9010501]. These diagnostic approaches collectively enhance the accuracy and timeliness of identifying sialoadenitis, guiding effective therapeutic interventions.
Differential Diagnosis
Differentiating sialoadenitis from other conditions is crucial for appropriate management. Common differential diagnoses include dental and gingival problems such as periodontal disease, caries, and malocclusion, which can also lead to hypersalivation, particularly in pediatric patients [PMID:42017726]. Other conditions to consider include autoimmune disorders affecting salivary glands, infections (bacterial or viral), and neurological disorders that impact swallowing and saliva control mechanisms. Gastroesophageal reflux disease (GERD) and certain medications can also induce sialorrhoea, necessitating a thorough history and physical examination to rule out these possibilities. In clinical practice, distinguishing between these conditions often relies on detailed patient history, imaging studies (such as ultrasound or MRI), and specific salivary gland function tests to pinpoint the exact etiology and guide targeted treatment strategies.
Management
The management of sialoadenitis encompasses a spectrum of approaches tailored to the severity and underlying cause of the condition. Surgical interventions, including submandibular gland removal and duct transposition, remain the most common treatments, accounting for approximately 42.1% of cases, with conservative treatments like topical medications resolving about 21.0% of cases [PMID:40818136]. Pharmacological interventions, particularly glycopyrronium, have shown significant efficacy in managing sialorrhoea, with over 80% of pediatric patients experiencing substantial improvements in quality of life measures like the Drooling Impact Scale (DIS) over extended follow-up periods [PMID:39888937]. Adverse effects, notably constipation, are common but manageable during dose titration [PMID:39888937].
Advanced treatments such as botulinum toxin type A injections offer targeted relief, particularly in cases where surgical options are less favorable. Studies indicate that bilateral submandibular gland injections can lead to marked reductions in salivation, with low morbidity and no serious adverse events reported in several case series [PMID:16924280]. Foreign body-induced sialoadenitis necessitates meticulous identification and removal to prevent recurrent issues and further complications [PMID:27438453]. Multidisciplinary care, involving specialists in dentistry, neurology, and pediatrics, ensures comprehensive management, addressing both the immediate symptoms and underlying causes. Tailored interventions, from conservative management to surgical options, are essential to optimize patient outcomes and quality of life.
Complications
Management strategies for sialoadenitis, while effective, can introduce various complications that clinicians must monitor closely. Glycopyrronium treatment, while highly effective in reducing sialorrhoea, is associated with notable side effects, particularly constipation, reported in approximately 20.5% of pediatric patients [PMID:39888937]. Other common adverse effects include vomiting and dry mouth, though these are less frequent [PMID:39888937]. Surgical interventions, such as submandibular gland removal and duct transposition, generally yield favorable outcomes with uneventful recoveries, but transient complications can arise. For instance, post-surgical deficits in lingual nerve function and mild tongue movement limitations have been observed in some cases, though facial nerve involvement remains rare [PMID:19231775]. Botulinum toxin injections, while minimally invasive and effective, can occasionally lead to minor side effects, though serious adverse events are rare [PMID:16924280]. Regular follow-up and vigilant monitoring are crucial to address these complications promptly and ensure optimal patient recovery.
Prognosis & Follow-up
The prognosis for patients with sialoadenitis varies based on the severity of the condition and the effectiveness of the chosen treatment modality. Long-term follow-up studies indicate sustained improvements in quality of life measures, such as significant reductions in drooling impact scores observed over extended periods, often lasting several years [PMID:39888937, PMID:17078897, PMID:11737025]. For instance, patients treated with glycopyrronium showed sustained benefits in DIS scores from initial assessments through long-term follow-ups, highlighting the durability of pharmacological interventions [PMID:39888937]. Surgical interventions, including submandibular gland removal and duct transposition, have demonstrated favorable cosmetic outcomes and no recurrence of tumors in follow-up periods averaging 14.1 months to four years, underscoring their effectiveness in managing severe cases [PMID:19231775, PMID:17078897]. Regular follow-up appointments are essential to monitor for recurrence and manage any emerging complications, ensuring sustained positive outcomes and continued improvement in patients' quality of life.
Special Populations
Sialorrhoea significantly impacts pediatric populations, particularly those with neurodisabilities, affecting not only their physical well-being but also their psychological and social development. Children with conditions like cerebral palsy often experience severe sialorrhoea, which can profoundly affect their quality of life and necessitate specialized management strategies [PMID:42017726, PMID:38214675]. Glycopyrronium treatment has shown promising results in reducing drooling impacts in these children, with notable improvements observed within weeks of initiation [PMID:38214675]. Additionally, botulinum toxin type A injections have emerged as a minimally invasive yet effective option, providing relief with manageable side effects [PMID:16924280]. Psychological support for both children and their families is crucial, as the condition can lead to significant emotional distress and social isolation. Tailored interventions that address developmental delays in saliva control mechanisms, alongside comprehensive multidisciplinary care, are essential for optimizing outcomes in these vulnerable populations.
Key Recommendations
These recommendations aim to guide clinicians in providing evidence-based, patient-centered care for sialoadenitis, balancing therapeutic efficacy with safety and quality of life considerations.
References
1 Panico JC, Andrade BA, Lazos J, Martin R, Piemonte E, Lopes CA et al.. Suppurative Stomatitis [Cheilitis Glandularis]: an underreported entity. Medicina oral, patologia oral y cirugia bucal 2025. link 2 Fayoux P, Dinomais M, Shaw H, Villain F, Schwartz D, Gautheron V et al.. Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open-label study extension of the SALIVA trial. Developmental medicine and child neurology 2025. link 3 Maru M, Sato K. Characterization of a coronavirus isolated from rats with sialoadenitis. Archives of virology 1982. link 4 Sulaiman G, Mahroos AAG, Othman A, Siddiqui EU. Paediatric Sialorrhoea. JPMA. The Journal of the Pakistan Medical Association 2026. link 5 Fayoux P, Dinomais M, Shaw H, Villain F, Schwartz D, Rondeau S et al.. Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: A randomized, double-blind, placebo-controlled trial. Developmental medicine and child neurology 2024. link 6 Ozturk K, Erdur O, Aksoy C. Foreign Body of Submandibular Gland. The Journal of craniofacial surgery 2016. link 7 Chen WL, Yang ZH, Wang YJ, Huang ZQ, Wang YY. Removal of the submandibular gland using a combined retroauricular and transoral approach. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2009. link 8 Syeda F, Ahsan F, Nunez DA. Quality of life outcome analysis in patients undergoing submandibular duct repositioning surgery for sialorrhoea. The Journal of laryngology and otology 2007. link 9 Shetty S, Dawes P, Ruske D, Al-qudah M, Lyons B. Botulinum toxin type-A (Botox-A) injections for treatment of sialorrhoea in adults: a New Zealand study. The New Zealand medical journal 2006. link 10 Lim M, Mace A, Nouraei SA, Sandhu G. Botulinum toxin in the management of sialorrhoea: a systematic review. Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2006. link 11 Kosaka M, Enjo M, Kamiishi H. Bilateral parotid sialoadenitis with gonial hypertrophy. Scandinavian journal of plastic and reconstructive surgery and hand surgery 2003. link 12 Glickman S, Deaney CN. Treatment of relative sialorrhoea with botulinum toxin type A: description and rationale for an injection procedure with case report. European journal of neurology 2001. link 13 Johnson H, King J, Reddihough DS. Children with sialorrhoea in the absence of neurological abnormalities. Child: care, health and development 2001. link 14 Yamamoto H, Ishibashi K, Nakagawa Y, Maeda N, Zeng T, Robinson CP et al.. Detection of alterations in the levels of neuropeptides and salivary gland responses in the non-obese diabetic mouse model for autoimmune sialoadenitis. Scandinavian journal of immunology 1997. link 15 Yamada-Nosaka A, Fukutomi S, Uemura S, Hashida T, Fujishita M, Kobayashi Y et al.. Preliminary nuclear magnetic resonance studies on human saliva. Archives of oral biology 1991. link90025-p) 16 Sela J, Bab JA, Rosenmann E, Boss JH. Experimental allergic sialoadenitis. VIII. Acute parotitis following intraductal instillation of antiserum to salivary antigens in the rat. The Journal of pathology 1976. link
16 papers cited of 19 indexed.